Progyny Inc PGNY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PGNY is a good fit for your portfolio.
News
-
Progyny, Inc. to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
-
Progyny, Inc. Announces Third Quarter 2023 Results
-
The Broken Brown Egg and Progyny Launch 2023 Awareness, Hope, and Activism Grant™ to Help BIPOC Individuals and Couples Expand Their Families
-
Progyny, Inc. Announces Details for Its Third Quarter 2023 Results Report
-
Fertility manager Progyny stock gains as resumption of Menopur deliveries leads to raised guidance
Trading Information
- Previous Close Price
- $34.36
- Day Range
- $34.13–34.97
- 52-Week Range
- $28.03–44.95
- Bid/Ask
- $34.50 / $34.60
- Market Cap
- $3.31 Bil
- Volume/Avg
- 730,613 / 760,599
Key Statistics
- Price/Earnings (Normalized)
- 63.72
- Price/Sales
- 3.36
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.
- Sector
- Healthcare
- Industry
- Health Information Services
- Stock Style Box
- Small Growth
- Total Number of Employees
- 400
- Website
- https://www.progyny.com
Valuation
|
Metric
|
PGNY
|
|---|---|
Price/Earnings (Normalized) | 63.72 |
Price/Book Value | 6.38 |
Price/Sales | 3.36 |
Price/Cash Flow | 17.40 |
Price/Earnings
PGNY
Financial Strength
|
Metric
|
PGNY
|
|---|---|
Quick Ratio | 3.12 |
Current Ratio | 3.16 |
Interest Coverage | — |
Quick Ratio
PGNY
Profitability
|
Metric
|
PGNY
|
|---|---|
Return on Assets (Normalized) | 28.64% |
Return on Equity (Normalized) | 41.78% |
Return on Invested Capital (Normalized) | 39.84% |
Return on Assets
PGNY
Health Information Services Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
GEHC
| GE HealthCare Technologies Inc Common Stock | Lrcvfn | $31.6 Bil | |
VEEV
| Veeva Systems Inc Class A | Dhg | $28.7 Bil | |
MTHRF
| M3 Inc | Bqz | $10.9 Bil | |
MTHRY
| M3 Inc ADR | Xvltl | $10.9 Bil | |
PMCUF
| Pro Medicus Ltd | Gyzfdrf | $6.1 Bil | |
HQY
| HealthEquity Inc | Byfbfw | $5.9 Bil | |
TXG
| 10x Genomics Inc Ordinary Shares - Class A | Jjv | $5.4 Bil | |
RCM
| R1 RCM Inc | Fgbv | $4.6 Bil | |
DOCS
| Doximity Inc Class A | Spgphv | $4.5 Bil | |
EVH
| Evolent Health Inc Class A | Cnl | $3.3 Bil |